Lamivudine
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
1
Recruiting
0
Completed
1
Sites
4
Countries
2
Endpoints
13
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 13 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 3 of 13 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| ART-ADPilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease | Lamivudine Alzheimer’s disease | Alzheimer's disease | Ph 1/2 | Completed | 3 | May 2023 | 1 | results |
| NCT06519357A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI) | Lamivudine MCI / preclinical Alzheimer’s | MCI due to AD / prodromal AD | Ph 2 | Active, not recruiting | 1 | Sep 2025 | - |
Showing 1-2 of 2 trials